| Date | Title | | | 06/22/09 | Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August| Advisory Committee to Review Denosumab Data
THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration
(FDA) has asked the company to participate in a meeting of the Reproductive
Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The RHDAC will
review data supporting the Biologics License Application (BLA) for denosumab,
a RANK Ligand inhibitor for which Amgen is seeking approval for preventi... |
|  | | 06/17/09 | 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence|
2009 Awardees Recognized in Amgen Communities Across North America
THOUSAND OAKS, Calif., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the futu... |
| | | 06/08/09 | Amgen to Present at the Goldman Sachs Global Healthcare Conference| THOUSAND OAKS, Calif., June 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Goldman Sachs Global Healthcare Conference on
Wednesday, June 10, 2009 at the Grand Hyatt, New York City, N.Y., beginning at
9:00 a.m. Eastern Time. Roger M. Perlmutter, Amgen's Executive Vice President
of Research & Development, will present. Live audio of the presentation will
be available over the Internet and can be accessed from Amgen's Web site,
www.amgen.com, under Investors.
I... |
| | | 06/07/09 | New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP| BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today
released the results of a new study comparing Nplate(R) (romiplostim) to the
medical standard of care (SOC) in non-splenectomised adult patients with
chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious
autoimmune disorder characterised by low platelet counts in the blood
(thrombocytopenia), which can lead to serious bleeding events. The study
results show Nplate significantly reduced the incid... |
| |
|
